RC1012

Here, we reported our ongoing phase I clinical trial of RC1012 injection (allogeneic DNT cells) in patients with r/r AML (NCT05471323)...After lymphodepleting chemotherapy with fludarabine and cyclophosphamide, each patient received three infusions of HLA-mismatched DNT cells at 1... Allogeneic DNTs therapy are safe in clinical treatment and can reduce tumor burden after infusion with the increase of patient's DNT cells in complete remission and partial remission patients. These findings warrant the allogeneic DNTs as a novel adjuvant therapy with allo-HSCT to enhance the treatment efficacy in r/r AML. The finding of TIGIT, PD-1, CD57 molecules were increased on patients' T cells indicated that the combination of DNTs with immune checkpoint inhibitors may further improve the DNTs efficacy in r/r AML patients.

P1, N=36, Recruiting, Guangdong Ruishun Biotech Co., Ltd | Trial primary completion date: Dec 2022 --> Dec 2023

P1/2, N=72, Recruiting, Guangdong Ruishun Biotech Co., Ltd | Active, not recruiting --> Recruiting

P1/2, N=72, Active, not recruiting, Guangdong Ruishun Biotech Co., Ltd